Toronto Dominion Bank
NGM

Toronto Dominion Bank’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Toronto Dominion Bank’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25
Closed -$27 – 1873
2023
Q3 		$27 Hold
25
– – ﹤0.01% 1776
2023
Q2 		$0 Buy
+25
New +$89 ﹤0.01% 1876

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Toronto Dominion Bank's NGM Position: Q4 2023 in Review

Toronto Dominion Bank sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 25 shares — an estimated $27 sold.

Toronto Dominion Bank first reported a position in NGM in Q2 2023 and held it in 2 quarters. The position peaked at $27 in Q3 2023. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Toronto Dominion Bank reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Toronto Dominion Bank sold 25 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $27.
  • Toronto Dominion Bank first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Toronto Dominion Bank's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $27 in Q3 2023.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.